New research could improve the effectiveness of flu vaccines and therapies

Like a flu vaccine, an effective HIV vaccine needs to protect against multiple strains.

A new study led by scientists at The Scripps Research Institute (TSRI) is the first to show exactly how the drug Arbidol stops influenza infections.

Researchers have been trying for decades to develop a vaccine against the globally endemic hepatitis C virus (HCV). Now scientists at The Scripps Research Institute (TSRI) have discovered one reason why success has so far been elusive.

A series of new studies led by scientists at The Scripps Research Institute (TSRI) and the International AIDS Vaccine Initiative (IAVI) describe a potential vaccination strategy to jump-start the selection and evolution of broadly effective antibodies to prevent HIV infection.

Two new studies focus on finding new ways to stabilize proteins called HIV-1 surface antigens and in designing HIV-like particles to prompt the body to fight the real virus.

In a new study, a team led by scientists at The Scripps Research Institute (TSRI) tracked how a family of potent HIV-fighting antibodies develops over time. The research shows how a future vaccine might trigger the immune system to produce these antibodies more effectively.

Scientists from The Scripps Research Institute (TSRI) and the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) have found a way to induce antibodies to fight a wide range of influenza subtypes—work that could one day eliminate the need for repeated seasonal flu shots.

Scripps Research and Rockefeller Scientists Work on Obesity Therapy as Proof-of-Principle.

Cocaine-binding antibodies have shown some promise in their ability to neutralize cocaine toxicity, but their binding ability is severely impaired by high concentrations of the drug.